Irofulven
- Generic Name
- Irofulven
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18O3
- CAS Number
- 158440-71-2
- Unique Ingredient Identifier
- 6B799IH05A
- Background
A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
- Indication
Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
- Conditions
- Metastatic Castration-Resistant Prostate Cancer Patients
- Interventions
- Combination Product: Prednisolone 10 mg
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT03643107
- Locations
- 🇩🇰
Rigshospitalet, Dept. Of Oncology, Copenhagen, Denmark
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00374660
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
- Conditions
- Thyroid Cancer
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00124527
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00124566
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00003666
- Locations
- 🇺🇸
University of California San Diego Cancer Center, La Jolla, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Irofulven in Treating Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00003441
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2004-08-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003390
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer
- Conditions
- Cervical Cancer
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005070
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT00003786
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Michiana Hematology/Oncology P.C., South Bend, Indiana, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2012-08-09
- Target Recruit Count
- 3
- Registration Number
- NCT00003760
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Brooke Army Medical Center, Fort Sam Houston, Texas, United States
🇺🇸San Antonio Cancer Institute, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.